PA5-63890

antibody from Invitrogen Antibodies

Targeting: EHF ESE3, ESEJ

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-63890

Provider

Invitrogen Antibodies

Product name

EHF Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: MILEGGGVMN LNPGNNLLHQ PPAWTDSYST CNVSSGFFGG QWHEIHPQYW TKYQVWEWLQ HLLDTNQLDA NCIPFQEFDI NGEHL Highest antigen sequence identity to the following orthologs: Mouse - 92%, Rat - 94%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma.

Zhang T, Song X, Zhang Z, Mao Q, Xia W, Xu L, Jiang F, Dong G
Oncogenesis 2020 Oct 17;9(10):92

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of EHF in human salivary gland tissue shows distinct nuclear positivity in glandular cells. Samples were probed using an EHF Polyclonal Antibody (Product # PA5-63890).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of EHF in human salivary gland and liver tissues using EHF Polyclonal Antibody (Product # PA5-63890). Corresponding EHF RNA-seq data are presented for the same tissues.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of EHF in human liver using EHF Polyclonal Antibody (Product # PA5-63890) shows low expression as expected.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 6 High expression of CRC (ELF3/EHF/TGIF1-High) were associated with poor prognosis on patients with LUAD. A qRT-PCR analysis of ELF3, EHF, and TGIF1 among 20 pairs of matched lung adenocarcinoma and adjacent normal tissue. B Correlation analyses conducted between the mRNA expression of ELF3, EHF, and TGIF1 from ( A ). C ELF3, EHF, and TGIF1 were detected in peritumoral tissue and representative LUAD samples by immunohistochemistry staining. Scale bar, 100 mum. D Kaplan-Meier analysis of overall survival of LUAD patients (TCGA-LUAD) with low (low expression of ELF3, EHF, and TGIF1, n = 78) and high (high expression of ELF3, EHF, and TGIF1, n = 52) ELF3/EHF/TGIF1 expression (log-rank test, two-sided). E Left panel: a schematic diagram showing the key targets and small-molecule inhibitors of SE. JQ1 and OTX015 targeting BRD4, THZ1 targeting CDK7; CBPC30 targeting EP300. Right panel: CRCs are assembled as fully interconnected loops of auto-regulated TFs. Schematic graph of the model of interconnected circuitry, with hexagons representing enhancer elements and proteins, respectively. Data in ( A ) were mean +- SD; n = 3 independent experiments, two-tailed paired Student's t test, ns not significant, * p < 0.05; ** p < 0.01; *** p < 0.001 ( B ) R, Pearson correlation coefficients ( r ) and p values.